selective phosphodiesterase 4 inhibitor (GSK256066)	placebo	EAR (early response)	723	894	GSK256066 significantly reduced the EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo.
selective phosphodiesterase 4 inhibitor (GSK256066)	placebo	fall in minimum and weighted mean FEV1	550	721	GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo
selective phosphodiesterase 4 inhibitor (GSK256066)	placebo	fall in minimum and weighted mean FEV1	550	722	GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.
selective phosphodiesterase 4 inhibitor (GSK256066)	placebo	LAR (late response)	550	722	GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo.
selective phosphodiesterase 4 inhibitor (GSK256066)	placebo	Methacholine reactivity at 24 hrs post allergen challenge	14160	14414	Methacholine reactivity at 24 hrs post allergen challenge was not different after treatment with GSK256066 compared to placebo; the PC20 was 0.31 compared to 0.39 mg/mL respectively, geometric mean (95% CI) doubling dose difference -0.31 (-1.18 to 0.57).
selective phosphodiesterase 4 inhibitor (GSK256066)	placebo	responses to allergen challenge in mild asthmatics	14160	14414	Methacholine reactivity at 24 hrs post allergen challenge was not different after treatment with GSK256066 compared to placebo; the PC20 was 0.31 compared to 0.39 mg/mL respectively, geometric mean (95% CI) doubling dose difference -0.31 (-1.18 to 0.57).
